CytomX Therapeutics, Inc.
204 articles about CytomX Therapeutics, Inc.
-
CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported third quarter 2022 financial results and provided a business update.
-
CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting
11/7/2022
CytomX Therapeutics, Inc. announced that preclinical data for CX-801, its conditionally activated cytokine program, will be presented at the Society for Immunotherapy of Cancer Annual Meeting in Boston, Massachusetts.
-
CytomX Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/2/2022
CytomX Therapeutics, Inc., a leader in the field of conditionally activated oncology therapeutics, announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in the following investor conferences in November.
-
CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022
11/1/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report third quarter 2022 financial results on Tuesday, November 8, 2022, after the close of U.S. markets.
-
CytomX Therapeutics Announces Phase 1 Data Update for anti-CTLA-4 Probody® Therapeutic BMS-986249
9/12/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that its collaborator, Bristol Myers Squibb, presented updated Phase 1 results with BMS-986249, a Probody® therapeutic version of ipilimumab, the anti-CTLA-4 antibody, at the ESMO Congress 2022 in Paris, France.
-
CytomX Therapeutics Presents Overview of Conditionally-Activated Antibody-Drug Conjugate (ADC) Programs Including Next Generation EpCAM-Targeting CX-2051
9/7/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the Company presented advances within its conditionally-activated ADC portfolio, including the next generation EpCAM-ADC, CX-2051, at the World ADC conference taking place September 6-9, 2022, in San Diego, CA.
-
CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported second quarter 2022 financial results and provided a business update.
-
CytomX Therapeutics to Present at Upcoming Virtual August Investor Conferences
8/3/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will virtually participate in the following investor conferences in August.
-
CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
7/28/2022
CytomX Therapeutics, Inc. today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.
-
CytomX Therapeutics is shifting its focus to preclinical and early clinical studies, emphasizing alliances and slashing its workforce by about 40% to extend cash flow to 2025.
-
CytomX Therapeutics Provides Strategic Update - July 13, 2022
7/13/2022
CytomX Therapeutics, Inc., a leader in the field of conditionally activated oncology therapeutics, announced plans to focus on its emerging pre-clinical and early clinical pipeline and to realign its capital resources to drive these efforts.
-
CytomX Therapeutics Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer
7/6/2022
CytomX Therapeutics, Inc. announced that the Phase 2 study of praluzatamab ravtansine in patients with hormone receptor-positive /human epidermal growth factor receptor 2 -non-amplified breast cancer met its primary efficacy endpoint of confirmed objective response rate of greater than 10 percent by central radiology review.
-
CytomX Therapeutics Announces New Employment Inducement Grants - June 16, 2022
6/16/2022
CytomX Therapeutics, Inc. announced that on June 15, 2022, the Company granted two new employees options to purchase a total of 109,000 shares of the Company’s common stock at an exercise price per share equal to $1.72, which was the closing trading price on June 15, 2022, the date of the grant.
-
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
6/1/2022
CytomX Therapeutics, Inc. announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors- EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic -
5/26/2022
CytomX Therapeutics, Inc. today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 ( NCT05387265 ).
-
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported first quarter 2022 financial results and provided a business update.
-
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
4/28/2022
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the close of U.S. markets.
-
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
4/14/2022
CytomX Therapeutics, Inc. announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.
-
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
3/17/2022
CytomX Therapeutics, Inc. today announced that preclinical data supporting the ongoing development of its conditionally activated cytokine program will be presented at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana.